Background/Aims: The present study investigated the mechanism by which peroxynitrite impairs vascular function through the nitric oxide (NO)/soluble guanylate cyclase (sGC)/cGMP pathway. Methods: Mechanical responses of rat external iliac arteries without endothelium were studied under exposure to peroxynitrite. cGMP concentrations were determined by enzyme immunoassay. Results: Relaxation induced by BAY 41-2272 (sGC stimulator) was impaired under exposure to peroxynitrite, whereas that by BAY 60-2770 (sGC activator) was enhanced. These responses were correlated with tissue levels of cGMP. Effects of peroxynitrite on the relaxant responses to BAY compounds were also observed in the presence of superoxide dismutase (SOD) or tempol, both of which scavenge a certain kind of reactive molecules other than peroxynitrite. As is the case with the relaxant response to BAY 41-2272, acidified NaNO2- and nitroglycerin-induced relaxations were markedly attenuated by exposing the arteries to peroxynitrite, which was not abolished by preincubation with SOD or tempol. On the other hand, peroxynitrite exposure had no effect on the 8-Br-cGMP-induced vasorelxation. Conclusion: These findings suggest that peroxynitrite interferes with the NO/sGC/cGMP pathway by altering the redox state of sGC. It is likely that peroxynitrite can shift the sGC redox equilibrium to the NO-insensitive state in the vasculature.

Keywords:
Peroxynitrite, Nitric oxide, Soluble guanylate cyclase, cGMP, Vasorelaxation
1.
Denninger JW, Marletta MA: Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334-350.
2.
Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B: Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996;50:1-5.
3.
Ignarro LJ, Adams JB, Horwitz PM, Wood KS: Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem 1986;261:4997-5002.
4.
Wunder F, Stasch JP, Hütter J, Alonso-Alija C, Hüser J, Lohrmann E: A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal Biochem 2005;339:104-112.
5.
Schmidt P, Schramm M, Schröder H, Stasch JP: Preparation of heme-free soluble guanylate cyclase. Protein Expr Purif 2003;31:42-46.
6.
Rapoport RM, Draznin MB, Murad F: Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983;306:174-176.
7.
Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, Wright J, Stasch JP, Abman SH: Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2011;301:L755-L764.
8.
Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH: Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561.
9.
Kwak CJ, Kubo E, Fujii K, Nishimura Y, Kobuchi S, Ohkita M, Yoshimura M, Kiso Y, Matsumura Y: Antihypertensive effect of French maritime pine bark extract (Flavangenol): possible involvement of endothelial nitric oxide-dependent vasorelaxation. J Hypertens 2009;27:92-101.
10.
Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768.
11.
Stasch JP, Hobbs AJ: NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009;191:277-308.
12.
Schmidt HH, Schmidt PM, Stasch JP: NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 2009;191:309-339.
13.
Zhou L, Xiang W, Potts J, Floyd M, Sharan C, Yang H, Ross J, Nyanda AM, Guo Z: Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic Biol Med 2006;41:1384-1391.
14.
Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001;44:834-838.
15.
Sucu N, Unlü A, Tamer L, Aytacoglu B, Ercan B, Dikmengil M, Atik U: 3-Nitrotyrosine in atherosclerotic blood vessels. Clin Chem Lab Med 2003;41:23-25.
16.
Alvarez B, Radi R: Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003;25:295-311.
17.
Fritz BG, Hu X, Brailey JL, Berry RE, Walker FA, Montfort WR: Oxidation and loss of heme in soluble guanylyl cyclase from Manduca sexta. Biochemistry 2011;50:5813-5815.
18.
Cabassi A, Dumont EC, Girouard H, Bouchard JF, Le Jossec M, Lamontagne D, Besner JG, de Champlain J: Effects of chronic N-acetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J Hypertens 2001;19:1233-1244.
19.
Korkmaz S, Loganathan S, Mikles B, Radovits T, Barnucz E, Hirschberg K, Li S, Hegedüs P, Páli S, Weymann A, Karck M, Szabó G: Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta. J Cardiovasc Pharmacol Ther 2013;18:70-77.
20.
Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, Taylor LM: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-3049.
21.
Tawa M, Shimosato T, Iwasaki H, Imamura T, Okamura T: Different influences of extracellular and intracellular superoxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries. J Cardiovasc Pharmacol 2014, in press.
22.
Tawa M, Geddawy A, Shimosato T, Iwasaki H, Imamura T, Okamura T: Soluble guanylate cyclase redox state under hypoxia or hypoxia/reoxygenation in isolated monkey coronary arteries. J Pharmacol Sci 2014;125:169-175.
23.
Toda N, Okamura T: Mechanism of neurally induced monkey mesenteric artery relaxation and contraction. Hypertension 1992;19:161-166.
24.
Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M: NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-215.
25.
Knorr A, Hirth-Dietrich C, Alonso-Alija C, Härter M, Hahn M, Keim Y, Wunder F, Stasch JP: Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 2008;58:71-80.
26.
Mónica FZ, Rojas-Moscoso J, Porto M, Schenka AA, Antunes E, Cogo JC, De Nucci G: Immunohistochemical and functional characterization of nitric oxide signaling pathway in isolated aorta from Crotalus durissus terrificus. Comp Biochem Physiol C Toxicol Pharmacol 2012;155:433-439.
27.
Carroll RT, Galatsis P, Borosky S, Kopec KK, Kumar V, Althaus JS, Hall ED: 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol) inhibits peroxynitrite-mediated phenol nitration. Chem Res Toxicol 2000;13:294-300.
28.
Bonini MG, Mason RP, Augusto O: The Mechanism by which 4-hydroxy-2,2,6,6-tetramethylpiperidene-1-oxyl (tempol) diverts peroxynitrite decomposition from nitrating to nitrosating species. Chem Res Toxicol 2002;15:506-511.
29.
Fernhoff NB, Derbyshire ER, Marletta MA: A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase. Proc Natl Acad Sci U S A 2009;106:21602-21607.
30.
Sayed N, Baskaran P, Ma X, van den Akker F, Beuve A: Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci U S A 2007;104:12312-12317.
31.
Mayer B, Kleschyov AL, Stessel H, Russwurm M, Münzel T, Koesling D, Schmidt K: Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol Pharmacol 2009;75:886-891.
32.
Choi H, Tostes RC, Webb RC: Thioredoxin reductase inhibition reduces relaxation by increasing oxidative stress and S-nitrosylation in mouse aorta. J Cardiovasc Pharmacol 2011;58:522-527.
33.
Negash S, Gao Y, Zhou W, Liu J, Chinta S, Raj JU: Regulation of cGMP-dependent protein kinase-mediated vasodilation by hypoxia-induced reactive species in ovine fetal pulmonary veins. Am J Physiol Lung Cell Mol Physiol 2007;293:L1012-L1020.
34.
Aggarwal S, Gross CM, Kumar S, Datar S, Oishi P, Kalkan G, Schreiber C, Fratz S, Fineman JR, Black SM: Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration. J Cell Physiol 2011;226:3104-3113.
35.
Alvarez MN, Piacenza L, Irigoín F, Peluffo G, Radi R: Macrophage-derived peroxynitrite diffusion and toxicity to Trypanosoma cruzi. Arch Biochem Biophys 2004;432:222-232.
36.
Ruetten H, Zabel U, Linz W, Schmidt HH: Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 1999;85:534-541.
37.
Zheng H, Yu YS: Chronic hydrogen-rich saline treatment attenuates vascular dysfunction in spontaneous hypertensive rats. Biochem Pharmacol 2012;83:1269-1277.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.